CPTx is a genetic medicines company redefining how we treat disease using immune-silent, redosable ssDNA as the foundation for safe, durable in vivo therapies.
Our lead program is a new kind of in vivo CAR-T cell therapy using immune-silent ssDNA delivered with LNPs, enabling repeat dosing, and controllable long-lasting effects. Through alliances with innovative companies, we are also collaborating to develop novel genetic medicines.
Our mission is to make complex genetic medicines safe, scalable, and accessible, starting with in vivo CAR-T.
We believe in a world where cell and gene therapies do not require a hospital bed or a million-dollar price tag. Our science is built to go over barriers and raise standards.
How we work
CPTx unites world-class ssDNA engineering, seasoned drug developers, and manufacturing to bring innovative genetic medicines from the laboratory to the clinic.
CEO & Founder
CEO & Founder
Dr. Hendrik Dietz founded CPTx in 2021 to carry forward 15 years of research and development of single stranded DNA programming and manufacturing processes. Committed to transforming theoretical ideas into practical applications, at CPTx he has assembled the talent and infrastructure needed to advance this work to solve deep challenges in the field of genetic medicines. Prior to CPTx, Dr. Dietz held faculty and research positions at Technical University of Munich (TUM) and Harvard School of Medicine, and is the recipient of numerous honors and awards, including the Gottfried Wilhelm Leibniz Prize. He received a PhD in Physics from TUM.
Chief Operating Officer
Chief Operating Officer
As Chief Operating Officer of CPTx, Dr. Grant Boldt leads the company’s innovation-driven R&D in next-generation genetic medicines, guiding programs from discovery and design through delivery, manufacturing, and preparation for first-in-human studies. His role integrates scientific vision with organizational leadership to advance pioneering approaches in genetic medicine. Dr. Boldt joined CPTx in early 2024, bringing decades of experience at the intersection of biotechnology R&D and pharmaceutical manufacturing strategy. He previously served as Vice President of Research Pharmaceuticals at Sigma-Aldrich, Senior Vice President and Business Unit Head of Biologics at Lonza, and Executive Vice President of Biologics at Avantor. Over the course of his career, he has authored numerous scientific publications and patents and has been a frequent speaker, with a consistent focus on translating innovative science into transformative therapeutic applications. Dr. Boldt received his PhD in Chemical Biology from Scripps Research Institute, CA, US.
Chief Business Officer
Chief Business Officer
David Maier joined CPTx in 2025 with more than 20 years of pharma and biotech industry leadership experience. David has led and supported multiple new therapeutics launches at Novartis in oncology, vaccines, and ophthalmology, and has driven growth as a commercial general manager at Novartis and West Pharmaceutical Services. He has executed acquisitions, partnerships, divestitures, and restructurings at Lonza and Novartis, and advised more than a dozen life-sciences companies on strategy and transactions at L.E.K. Consulting. David served as an officer in the U.S. Marine Corps; he holds degrees from Harvard and Cornell.
Chairman of the Board
Chairman of the Board
Dr. Oschmann is a seasoned executive with extensive experience in biopharma, life science tools, and specialty chemicals. He was the Chairman and CEO at Merck KGaA, where he spearheaded the company’s transformation into a leading science and technology firm. Under his leadership, Merck introduced two blockbuster products in neuroscience and oncology. Following his seven-year tenure at Merck, he became chairman of UCB and AiCuris, and he currently works as a partner at the private equity firm Armira. His earlier career included senior roles at Merck & Co. (MSD), including President of Emerging Markets and President of Europe/Middle East/Africa, after starting in R&D at MSD and working in research at the International Atomic Energy Agency. He earned a doctorate (DVM) from the University of Munich.
We are scientists, engineers, and builders who have spent our careers turning synthetic biology into real medicine. We have launched products, scaled biomanufacturing, and led platform development from seed to clinic.
We set out in 2021 to translate more than 15 years of foundational research into ssDNA engineering, programming and manufacturing into a company pioneering the development of novel genetic medicines. With headquarters, labs, and manufacturing in Munich, Germany, and an office in South San Francisco, California, we are leading the field of single-stranded DNA engineering, synthesis, and therapeutics development, built on a deep body of peer-reviewed research and robust intellectual property and know-how.
Reach out any time to express interest in joining our team, partnering, or investing.